Pain Pathways (DRG)
Cav3.2 T-type calcium channels in dorsal root ganglion nociceptors
Cav3.2 — The Primary Pain Channel
01Channel Profile
02Key Evidence
- *Cav3.2 (CACNA1H) is the dominant T-type calcium channel in DRG nociceptors — it controls neuronal excitability at the peripheral pain sensing level (Snutch & Bhargava 2021i).
- *Cav3.2 expression and activity are significantly upregulated in both inflammatory and neuropathic pain models.
- *T-type channel blockers are effective analgesics in multiple pain models, confirming the causal role of these channels in pain signaling.
- *This is the same Cav3.2 channel that BERM identifies as the pathway-A transduction step — the channel sits at a bifurcation point where ~10% are open at resting potential (window current).
Sex Differences in Pain
03Sex-Differential Expression
- *Brain (Oxford) 2026i: functional Cav3.2 expression in human DRG neurons shows sex differences.
- *Female DRG neurons show more prominent Cav3.2 currents.
- *This aligns with the well-documented clinical observation that chronic pain conditions disproportionately affect women.
- *From the BERM perspective: if EMF perturbs Cav3.2 in DRG neurons, the sex-differential expression predicts stronger EMF-pain sensitization in females.
Chronic pain epidemic: hundreds of millions affected globally. This is one of the largest unresolved medical challenges worldwide.
EMF and Pain Sensitization
04Mechanism chain
EMF → Cav3.2 perturbation in DRG → Ca²⁺ influx ↑ → neuronal excitability ↑ → pain threshold ↓
05Unifying mechanism
The same T-type bifurcation mechanism that operates in Leydig cells (fertility) and thalamocortical neurons (sleep) operates in DRG nociceptors (pain). This is NOT a separate hypothesis — it is the same biophysical mechanism in a different cell type.
Sensitive topic — methodological note
Chronic pain affects hundreds of millions of people. The mechanism described here is a MECHANISTIC FINDING from the BERM framework — NOT a treatment recommendation. Do NOT present this as medical advice. Patients should consult their healthcare providers regarding pain management.
06Key prediction
Cav3.2 blocker attenuates EMF-induced pain sensitization in animal model. This is testable in existing neuropathic pain models by adding an EMF exposure arm and comparing Cav3.2 blocker efficacy with and without EMF.
All predictions →07TheraBionic connectioni
The TheraBionic device — FDA-approved for hepatocellular carcinoma — targets Cav3.2 channels with non-thermal EMF. This confirms that Cav3.2 responds to non-thermal EMF at therapeutic levels, providing independent validation that the channel is an EMF transducer.
Key references
- Cav3.2 in chronic pain (2021)i
- Brain 2026: Cav3.2 sex differences in human DRGi
- TheraBionic — eBioMedicine (2019)i